Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

Phase 3

Completed

Conditions: Graft-versus-Host Disease
Immune System Disorders

Interventions: Drug: Placebo
Drug: Mycophenolate Mofetil

Registration Number: NCT01002742

Lead Sponsor: Medical College of Wisconsin

Brief Summary: The study is a Phase III, randomized double blind, placebo controlled, and trial evaluating the addition of Mycophenolate mofetil (MMF) vs. placebo to systemic corticosteroids as initial therapy for acute Graft Vs Host Disease (GVHD). The primary endpoint will be GVHD free survival at Day 56 post randomization.

Detailed Description: Corticosteroids have been used as primary therapy for acute GVHD for many years. Historical published and unpublished data from Johns Hopkins, M. D. Anderson, University of Michigan and others defined an expected 35%-53% complete response (CR) at Day +28 of corticosteroid therapy for previously untreated patients with acute GVHD.

BMT CTN study 0302 (NCT00224874)was a randomized Phase II study evaluating etanercept, mycophenolate mofetil, denileukin diftitox or pentostatin in addition to corticosteroids. The results of that study suggested that mycophenolate mofetil produced the highest rates of CR at Day 28 and overall survival, supporting its evaluation in a Phase III study. Day 56 GVHD-free survival for the four treatment arms (all combining corticosteroids with one of the four study drugs) ranged from 39-71% across the four study arms.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 236

Inclusion Criteria

Acute GVHD developing after allogeneic hematopoietic stem cell transplant using either bone marrow, peripheral blood stem cells or cord blood. Recipients of non-myeloablative and myeloablative transplants are eligible.
Acute GVHD after planned donor lymphocyte infusion or planned T cell add back are eligible.
De novo acute GVHD requiring systemic therapy. GVHD is defined as the presence of skin rash and/or persistent nausea, vomiting, and/or diarrhea and/or cholestasis presenting in a context in which acute GVHD is likely to occur and where other etiologies such as drug rash, enteric infection, or hepatotoxic syndromes are unlikely or have been ruled out. Note that patients with stage I and II skin only (overall grade I) or isolated upper gastrointestinal (GI) involvement are eligible if the treating physician deems that systemic high-dose corticosteroid treatment is indicated.
The patient must have had no previous systemic immune suppressive therapy for treatment of acute GVHD except for a maximum 72 hours of prior corticosteroid therapy at >0.5mg/kg methylprednisolone or equivalent after the onset of acute GVHD.
Clinical status at enrollment to allow tapering of steroids to not less than 0.25 mg/kg/day prednisone (0.2 mg/kg/day methylprednisolone) at Day 28 of therapy.
Absolute neutrophil count (ANC) greater than 500/µL.
Written informed consent and/or assent from patient, parent or guardian.
Documentation that the assent document and education materials have been provided to, and reviewed with, patients between the ages of 7 and 17.
Patients of all ages are eligible.
Biopsy confirmation of GVHD is recommended, but not required. Enrollment should not be delayed for biopsy or pathology results unless these are to be used to decide about whether to treat for GVHD.

Exclusion Criteria

Patients receiving mycophenolate mofetil or mycophenolic acid (Myfortic) within seven days of screening for enrollment.
Patients with uncontrolled infections will be excluded. If a bacterial or viral infection is present, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. If a fungal infection is present, patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
Relapsed/persistent malignancy requiring rapid immune suppression withdrawal.
Patients with GVHD after an unplanned Donor Lymphocyte Infusion (DLI), i.e., DLI that was not part of their original transplant therapy plan, or DLI given for treatment of persistent or recurrent malignancy after transplantation.
Patients unlikely to be available at the transplantation center on Day 28 and 56 of therapy.
A clinical syndrome resembling de novo chronic GVHD developing at any time after allotransplantation.
Patients receiving other drugs for the treatment of GVHD.
Patients receiving methylprednisolone > 0.5 mg/kg/day (or 0.6 mg/kg/day prednisone) within 7 days before the onset of acute GVHD. If steroid therapy has been administered for treatment of a non-GVHD related condition and tapered to ≤ 0.5 mg/kg/day methylprednisolone (0.6 mg/kg/day prednisone) for seven or more days before the onset of acute GVHD, the patient is eligible.
Patients who are pregnant, breast feeding, or, if sexually active, unwilling to use effective birth control for the duration of the study. Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding, therefore breast feeding patients are not eligible.
Adults unable to provide informed consent.
Patients on dialysis.
Patients with severe hepatic Veno-Occlusive Disease (VOD) or sinusoidal obstruction syndrome who in the judgement of the treating physician are not expected to have normalized bilirubin by Day 56 after enrollment.
Patients with a history of intolerance/allergy to MMF.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Corticosteroids with placebo
Mycophenolate Mofetil	Mycophenolate Mofetil	Corticosteroids with Mycophenolate Mofetil

Primary Outcome Measures

Name	Time	Method
GVHD-free Survival	Day 56	Success is defined as alive and free of GVHD at day 56 after randomization, all others are considered to be a study failure.

Secondary Outcome Measures

Name	Time	Method
Treatment Related Mortality (TRM)	Year 1
Incidence of GVHD Flares Requiring Increased Therapy	Day 90	Flares are defined as any progression of acute GVHD after an initial response (i.e., earlier CR or PR) that requires re-escalation of steroid dosing, or initiation of additional topical or systemic therapy.
Incidence of Discontinuation of Immune Suppression Without Flare	Day 56, Day 180 and Day 360 post-treatment
Incidence of Topical/Non-absorbable Therapy	Day 56
Incidence of Systemic Infections	6 Months	Number of participants that experienced at least one infection.
Change in Patient Reported Outcomes From Enrollment to Day 56	Day 56
Percentage of Surviving Participants With Complete Response (CR)	Days 14, 28, and 56	CR is defined as a score of 0 for the GVHD grading in all evaluable organs.
Incidence of Epstein-Barr Virus (EBV)-Associated Lymphoma	12 months
Disease-Free Survival (DFS) Post-Randomization	Year 1	DFS includes death or progression/relapse of malignancy
Cumulative Steroid Dose	Days 28 and 56	The cumulative steroid dose for each patient will be calculated by adding the doses (end of each week's dose) for each of the first four weeks of treatment, divided by the number of days of survival during this interval. The cumulative steroid dose was calculated for all patients per treatment arm and compared.
Overall GVHD-free Survival Post-randomization	Months 6 and 12
Incidence of Chronic GVHD	12 months post-randomization
Cumulative Incidence of a Severe/Life-threatening/Fatal Infections	Year 1
Incidence of Cytomegalovirus (CMV) Reactivation	Year 1

Trial Locations

Locations (36): BMT Program at Northside Hospital
🇺🇸
Atlanta, Georgia, United States
Dana Farber Cancer Institute, Brigham & Women's Hospital
🇺🇸
Boston, Massachusetts, United States
Fred Hutchinson Cancer Research Center
🇺🇸
Seattle, Washington, United States
Ohio State University
🇺🇸
Columbus, Ohio, United States
Stanford Hospital and Clinics
🇺🇸
Stanford, California, United States
University of Iowa Hospitals and Clinics
🇺🇸
Iowa City, Iowa, United States
Johns Hopkins University
🇺🇸
Baltimore, Maryland, United States
Indiana BMT at Beech Grove
🇺🇸
Beech Grove, Indiana, United States
University of Pennsylvania Cancer Center
🇺🇸
Philadelphia, Pennsylvania, United States
Rush University Medical Center
🇺🇸
Chicago, Illinois, United States
Tufts Medical Center
🇺🇸
Boston, Massachusetts, United States
Washington University, Barnes Jewish Hospital
🇺🇸
Saint Louis, Missouri, United States
Memorial Sloan-Kettering Cancer Center
🇺🇸
New York, New York, United States
DFCI, Massachusetts General Hospital
🇺🇸
Boston, Massachusetts, United States
Levine Children's Hospital, Carolinas Medical Center
🇺🇸
Charlotte, North Carolina, United States
Hackensack Univ. Medical Center
🇺🇸
Hackensack, New Jersey, United States
Baylor University Medical Center
🇺🇸
Dallas, Texas, United States
University of Minnesota
🇺🇸
Minneapolis, Minnesota, United States
Duke University Medical Center
🇺🇸
Durham, North Carolina, United States
University of Texas, MD Anderson Cancer Research Center
🇺🇸
Houston, Texas, United States
Texas Transplant Institute
🇺🇸
San Antonio, Texas, United States
University of California San Diego Medical Center
🇺🇸
La Jolla, California, United States
University of Maryland Medical Systems
🇺🇸
Baltimore, Maryland, United States
Weill Cornell Medical College, NY Presbyterian Hospital
🇺🇸
New York, New York, United States
Ann & Robert Lurie Children's Hospital of Chicago
🇺🇸
Chicago, Illinois, United States
City of Hope National Medical Center
🇺🇸
Duarte, California, United States
Avera Hematology & Transplant Center
🇺🇸
Sioux Falls, South Dakota, United States
Colorado Blood Cancer Institute
🇺🇸
Denver, Colorado, United States
University of Florida College of Medicine
🇺🇸
Gainesville, Florida, United States
Oregon Health and Science University
🇺🇸
Portland, Oregon, United States
Medical College of Wisconsin
🇺🇸
Milwaukee, Wisconsin, United States
University of Michigan Medical Center
🇺🇸
Ann Arbor, Michigan, United States
Mayo Clinic
🇺🇸
Rochester, Minnesota, United States
University of North Carolina Hospital at Chapel Hill
🇺🇸
Chapel Hill, North Carolina, United States
Virginia Commonwealth University
🇺🇸
Richmond, Virginia, United States
Medical University of South Carolina
🇺🇸
Charleston, South Carolina, United States